Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 16 |
| Active Pipeline (Recruiting Now) | 13 (9) |
| Completed vs Stopped Early | 0 / 3 (18.8%) |
| Median Closed Actual Enrollment | 21 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Beijing Cancer Hospital | Beijing, Beijing Municipality | 5 |
| Fudan University Shanghai Cancer Center | Shanghai, Shanghai Municipality | 3 |
| Liaocheng People's hospital | Liaocheng, Shandong | 2 |
Explore interactive annual charts and M&A subsidiary rollups in the LaNova Medicines Limited Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.